Safety of the RTS,S/AS02A Malaria Vaccine in Mozambican Children During a Phase IIb Trial

This study, published in the journal Vaccine, evaluated the safety of the RTS,S/AS02A malaria vaccine in a proof of concept Phase IIb trial in Mozambican children aged one to four years. Overall, the study results indicate that the vaccine has a good safety profile and is well tolerated when given in three doses to semi-immune children living in malaria-endemic areas.

Author(s): Sacarlal J, Aponte JJ, Aide P, et al.

Published: 2008

  • Visit web page (English)

    (Located at www.sciencedirect.com)

    Citation: Sacarlal J, Aponte JJ, Aide P, et al. Safety of the RTS,S/AS02A Malaria Vaccine in Mozambican Children During a Phase IIb Trial. Vaccine. 2008;26(2):174-184.